Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

174.12 +1.00 (+0.58%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
57 58 Next >
News headline image
Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
News headline image
Peeling Back The Layers: Exploring Biogen Through Analyst Insights ↗
 
Via Benzinga
News headline image
Evaluating Biogen: Insights From 17 Financial Analysts ↗
 
Via Benzinga
News headline image
Biogen Analysts Slash Their Forecasts After Q3 Results ↗
 
Via Benzinga
News headline image
Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum ↗
The biotech giant also raised full-year EPS guidance. 
Via Investor's Business Daily
News headline image
Looking Into Biogen's Recent Short Interest ↗
 
Via Benzinga
News headline image
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review ↗
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
News headline image
This Kraft Heinz Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
From Biogen Inc.
Via GlobeNewswire
News headline image
The Latest Analyst Ratings For Biogen ↗
 
Via Benzinga
News headline image
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights ↗
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
Via Benzinga
News headline image
Biogen (BIIB) Q3 2024 Earnings Call Transcript ↗
BIIB earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Biogen's Q3 Profit Beats Expectations On Lower Multiple Sclerosis Revenues But New Products Offset Losses, Raises Profit Outlook ↗
Biogen's Q2 revenue fell 3% to $2.47 billion exceeding estimates, with adjusted EPS of $4.08. Multiple sclerosis sales dipped, while new products buoyed performance. 
Via Benzinga
News headline image
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer
From Biogen Inc.
Via GlobeNewswire
News headline image
Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025
Robin Kramer, Chief Accounting Officer, to Succeed Him 
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
From Biogen Inc.
Via GlobeNewswire
News headline image
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock ↗
Fewer contenders means fewer constraints on expanding market share. 
Via The Motley Fool
News headline image
Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
From Biogen Inc.
Via GlobeNewswire
News headline image
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce ↗
Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus shifts to Huntington's Disease trial after setbacks in essential tremor and... 
Via Benzinga
Topics Workforce
News headline image
Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock ↗
Oppenheimer has initiated coverage on Larimar Therapeutics, emphasizing its lead program Nomlabofusp as a transformative therapy for Friedreich's ataxia. With a price target of $26, the company plans... 
Via Benzinga
News headline image
Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe ↗
Eli Lilly invests £279M in the UK to boost life sciences, while its Alzheimer's drug, donanemab, faces European regulatory hurdles amid ongoing trials and safety concerns. 
Via Benzinga
News headline image
Large-Cap Stocks In Trouble - Sunday, Oct. 13 ↗
Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns. 
Via Talk Markets
News headline image
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
Micron, Biogen, and Regeneron are three stocks that appear oversold and could present substantial buying opportunities for investors seeking recovery plays. 
Via MarketBeat
Topics ETFs Earnings
News headline image
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
From Biogen Inc.
Via GlobeNewswire
News headline image
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study ↗
Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues Alzheimer's development but expects Huntington's data soon. Stock drops 10.7%. 
Via Benzinga
News headline image
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
From Biogen Inc.
Via GlobeNewswire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.